Journal article
Genetic variation in IL28B: Impact on drug development for chronic hepatitis C infection
PJ Clark, AJV Thompson, JG McHutchison
Clinical Pharmacology and Therapeutics | WILEY | Published : 2010
Abstract
As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians, researchers,and health administrators to translate this information into knowledge in order to develop safer and more effective therapeutic strategies for all patients.
Grants
Funding Acknowledgements
[ "P.J.C and A.J.T. received funding support from the Duke Clinical Research Institute and the Richard B. Boebel Family Fund. A.J.T. received funding from the National Health and Medical Research Council of Australia and the Royal Australasian College of Physicians. The IDEAL study was funded by the Schering-Plough Research Institute, Kenilworth, New Jersey.", "J.G.M. has received research and grant support from Schering-Plough, Merck, and Roche. J.G.M. has received consulting fees and acted in an advisory capacity for Schering-Plough and Merck. J.G.M. and A.J.V.T. are co-inventors of a patent application based on the IL28B discovery. P.J.C. declared no conflict of interest." ]